With this extension, IXCHIQ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU).

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the Medicines and Healthcare products Regulatory ...

At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At ...

Until a safe, effective vaccine for rotavirus was developed in the 2000s, the virus led to 55,000 to 70,000 hospitalizations ...

With this extension, IXCHIQ ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU ...

SAN CARLOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the ...

serve as reservoirs of nosocomial pathogens and vectors for cross-transmission. Banknotes can serve as a potential source of pathogens, and paper currency recovered from hospitals was highly ...

Antimicrobial resistance is the ability of microorganisms such as bacteria, fungi or protozoans to grow despite exposure to antimicrobial substances designed to inhibit their growth. Microbes can ...